Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10653802 | 0.89 | SLC6A4 (0.54) | SLC6A4KCNH2SLC6A2SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL22797934 | 0.89 | SLC6A4 (0.44) | SLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL18611275 | 0.86 | PIK3CD (0.43) | SLC6A4KCNH2SLC6A2SLC6A3PIK3CD | |
| SCHEMBL297266 | 0.85 | SLC6A4 (0.49) | SLC6A4KCNH2SLC6A2SLC6A3PIK3CD | |
| SCHEMBL13911314 | 0.84 | ADH1A (0.44) | SLC6A4KCNH2PIK3CD | |
| SCHEMBL9144078 | 0.84 | SLC6A4 (0.50) | SLC6A4KCNH2SLC6A2SLC6A3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL3740415 | 0.83 | SLC6A4 (0.48) | SLC6A4KCNH2SLC6A2SLC6A3PIK3CD | |
| SCHEMBL19632137 | 0.83 | SLC6A4 (0.43) | SLC6A4KCNH2SLC6A2SLC6A3PIK3CD | |
| SCHEMBL9462350 | 0.82 | ADH1A (0.47) | PIK3CD | |
| SCHEMBL4281691 | 0.81 | ADH1A (0.48) | SLC6A4SLC6A2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200982-B1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | KNUST HENNER | 2011-01-27 | — | — | US | disclosed |
| EP-2200982-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009033995-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-03-19 | — | — | US | disclosed |
| EP-0897913-B1 | 4-carboxamido piperidine derivatives and their use as neurokinine antagonists | ASTRAZENECA AB (SE) | 2003-04-16 | — | — | EP | disclosed |
| EP-0667858-B1 | 4-CARBOXOAMIDO PIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS NEUROKININ ANTAGONISTS | ZENECA LTD (GB) | 1999-08-25 | — | — | EP | disclosed |
| EP-0897913-A1 | 4-carboxamido piperidine derivatives and their use as neurokinine antagonists | ZENECA LIMITED (GB) | 1999-02-24 | — | — | EP | disclosed |
| US-5576333-A | ASTHMA TREATMENT | ZENECA LIMITED (GB) | 1996-11-19 | — | — | US | disclosed |
| US-5559132-A | ANTAGONIST OF TACHYKININS AT THE NEUROKININ 2 RECEPTOR, ANTIASTHMA | ZENECA LIMITED (GB) | 1996-09-24 | — | — | US | disclosed |
| US-5559131-A | ANTAGONISTS OF TACHYKININS AT THE NEUROKININ 2 RECEPTOR, ANTIASTHMA | ZENECA LIMITED (GB) | 1996-09-24 | — | — | US | disclosed |
| EP-0667858-A1 | 4-CARBOXOAMIDO PIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1995-08-23 | — | — | EP | disclosed |
| US-5391556-A | Thrombin inhibitors | KARL THOMAE GMBH (DE) | 1995-02-21 | — | — | US | disclosed |
| WO-1994010146-A1 | 4-CARBOXOAMIDO PIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1994-05-11 | — | — | WO | disclosed |
| US-5214055-A | Analgesics, psychological disorders, anxiolytic agents | ADIR ET COMPAGNIE (FR) | 1993-05-25 | — | — | US | disclosed |
| US-5189045-A | Antiserotonine agent | ADIR ET COMPAGNIE (FR) | 1993-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | SLC6A4 201/4885KCNH2 43/4885SLC6A2 163/4885 |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | SLC6A4 201/4885KCNH2 43/4885SLC6A2 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.